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Introduction
Cryptophycins, isolated from blue-green algae (Nostoc sp.), are a new and potent tumor-selective class of tubulin-binding antimitotic agents that show excellent activity against MDR cancer cell lines and were exceptionally active against mammary derived tumors."
2 Cryptophycin-1 (1, Fig. 1 ) is the major cytotoxin in Nostoc sp. 3 ' 4 and displays IC 50 values in the pM range. Of special importance is the reduced susceptibility of the cryptophycins to P-glycoprotein mediated multiple drug resistance in comparison to vinblastine, colchicine, and paclitaxel. A structurally related compound cryptophycin-24, (2, Fig. 1 , also named arenastatin A), isolated from the Okinawan marine sponge Dysidea arenaria 5 and later from Nostoc sp. strain GSV 224,6 is also a potent inhibitor of tubulin polymerization. Cryptophycins are one of the best recent lead in the search for anticancer therapies. Formal and total syntheses of the cryptophycins have been published by several groups.
7 " Also, wide SAR studies of these molecules have been reported.I" 2 Although relatively little is known about the interactions of cryptophycins with tubulin, it is believed that the cryptophycins may interact in a manner different from those of other tubulin-binding antimitotic agents. 12' 4 For the development of these promising compounds into useful chemotherapeutic agents, detailed information about the binding domain of the cryptophycins is essential. Hence, we planned to prepare analogues with affinity labels at the two aromatic rings of the cryptophycin molecule. The information obtained will be used to search for effective bioactive candidates for in vitro and in vivo testing. We have already synthesized and evaluated three C16 side chain benzophenone"' and azido (meta and para)' 6 analogues of cryptophycin-24. Although these molecules are found to be better tubulin binding agents than parent cryptophycin-24, the photoaffinity labeling studies of these molecules failed due to the low abundance of the labeled molecule. As outlined in the original proposal, we then prepared the analogues possessing a photoaffinity labels at the C 10 side chain of cryptophycin-24.
Body
The retrosynthetic analysis for CIO aryl azido analogue of cryptophycin-24 (3) reveals that the precursor macrolide 4 can be assembled from two main building blocks, the octadienoate ester 5, and the peptide unit 6 derived from D-tyrosine derivative 12, P3-alanine 13 (Scheme 3), and L-leucic acid 15. The macrolide 4 on Heck coupling with the required aryl moiety followed by epoxidation can lead to the desired analogue of cryptophycin-24 (Scheme 1).
Silyl protection of the secondary alcohol 8 obtained from the aldehyde 7 through crotylboration followed by DDQ deprotection and DMP-oxidation furnished the aldehyde 10 (Scheme 2). Horner-Emmons homologation provided the a,p3-unsaturated tert-butyl ester 11.10 Deprotection of 11 with TBAF provided the desired hydroxy ester 5.
The second key synthon 6 was readily synthesized starting from commercially available N-Boc amino acid 12 (Scheme 3).1°17 Activation of 12 with DCC and N-hydroxysuccinimide followed by addition of 13-alanine 13 provided acid 14. EDCI activation and subsequent addition of L-leucic acid 15 provided acid 6 in two steps (Scheme 3).
Key synthons hydroxy ester 5 and depsipeptide fragment 6 were subjected to Yamaguchi coupling to afford intermediate 16 (Scheme 4) . Simultaneous deprotection of the tert-butyl ester and the N-Boc with trifluoroacetic acid produced the cyclization precursor and HBTU activation provided the desired macrocycle 4. Having the macrolide 4 in hand, we planned to couple it with different aryl halides to obtain various photoaffinity analogues of cryptophycin-24.
First, compound 4 was subjected to Heck coupling with phenyl iodide to get the desepoxy analogue 17a, which on epoxidation using dimethyl dioxirane farnished a diastereomeric (at, I3) mixture of epoxides 3a in 1 : 2 ratio in 65% (Scheme 5). Similarly, the alkene 4 reacted with two different iodides to afford para-acetylated oxymethylene aromatic alkene 17b and hydroxymethylene aromatic alkene 17c, respectively in 59% and 50% yields under the same Heck conditions. The epoxidation of these alkenes 17b and 17c with dimethyldioxirane provided epoxides 3b and 3c in a diastereomeric mixture of 1 : 2 and 1 : 9 (ca: P3), respectively in 40% and 40% yields.
The biological assays of CIO azido analogue of cryptophycin 3 showed that it is as active as cryptophycin-1 in a tubulin assembly assay (Table 1 ). This result assured that the separation of diastereomers will lead to a more active analogue and that it will be a candidate for labeling studies. As for cytotoxicity evaluation with MCF7 and MCF7-ADR, the results showed that 3a is half as active as cryptophycin 1 (1) for MCF7 and almost as active as cryptophycin 24 (2) for MCF7-ADR. We plan to prepare a radioactive form of photoaffinity analogue 3.
Key Research Accomplishments
Total synthesis of C10 azido analog of cryptophycin 24. Total syntheses of two analogs, where C1O-azido and C16-substituted aromatic side chains are attached, for further elucidation of the tubulin binding site and structure-activity relationships. Photoaffinity labeling studies with tubulin are being carried out in collaboration with Professor Richard Himes' laboratory in the Department of Molecular Biosciences. A new method for the synthesis of cryptophycins was developed also partly through support from this award (see first publication under reportable outcomes).
Reportable Outcomes
Synthesis of Cryptophycins via N-Acyl-beta-Lactam Macrolactonization, R. Vidya, M. J. Eggen, S. K. Nair, G. I. Georg, R. H. Himes, J. Org. Chem. 2003, 68, 9687-9693. 
Cryptophycin-1 (1) Cryptophycin-24 (2) This modular approach, involving a cyanide-initiated acyl-fl-lactam ring opening followed by cyclization, was successfully applied to the total synthesis of cryptophycin-24. The strategy was also used in an efficient synthesis of the 6,6-dimethyl -substituted dechlorocryptophycin-52. In this case, the cyanideinitiated ring opening of the bis-substituted 2-azetidinone followed by macrolactonization was achieved through a catalytic process.
Cryptophycins are potent, tumor-selective tubulin- formation of ring structures, possibly resulting from (2) For review: Eggen, M.: Georg, G. I. Med. Res. Rev. 2002, 22, curvature at two points per heterodimer, with local 85- precursors prompted us to examine the idea of deriving Cryptophycin-52 (3, Figure 1 ), a synthetic analogue 2 , 3 the fl-amino acid within the cryptophycin core from such that carries a gem-dimethyl group at the C6 position, a synthon. N-Acyl-fl-lactams were shown to be excellent displays increased hydrolytic stability and improved in sources for the incorporation of the phenylisoserine side vivo antitumor efficacy compared to cryptophycin-1,3 chain of paclitaxel, and readily reacted with the alkoxide Cryptophycin-52 displays high cytotoxicity against nuof baccatin III.51 A similar approach involving the inmerous cancer cell lines, including MDR cancer cell lines, tramolecular reaction 52 -4 of the fP-hydroxy group of the and is the most potent suppressor of microtubule dynamleucic acid ester with the activated acyl fP-lactam interics found to date. 26 . 27 Because of these attributes, crypmediate (5a, 5b) could represent a novel, concise aptophycin-52 (3) was selected for clinical development 3 and proach toward the synthesis of the macrolide core of the has been under evaluation. 28 Recently, a patent has cryptophycins and did provide the basis for our retrosyndescribed cryptophycin-308, the glycine ester of the thetic strategy (Figure 2 ). chlorohydrin of cryptophycin-1 (1, Figure 1) , as possess-
The retrosynthetic analysis for cryptophycins reveals ing better aqueous solubility, superior microtubule disthat the molecule can be assembled from three basic ruption, and lower toxicities than derivatives previously building blocks, octadienoate esters 6, L-leucic acid disclosed. The synthesis of cryptophycin-24 (2) started with Valeriote, F. A. Anti-Cancer Drugs 2002 , 13, 1061 -1068 secondary alcohol 9,31 which was coupled with acid provide ester 10 in 75% yield (Scheme 1). Oxidation of Cancer Chemother. Pharmacol. 2001, 47, 170-178. the primary alcohol, obtained after deprotection of the 4°,57 provided a diastereomeric propanediol by using a nine-step sequence reported mixture of cryptophycin-24 (2, j5:ct = 2:1) in 76% yield, earlier from our laboratory (17% overall yield). 4 1 Fragwhich was separated by reverse-phase HPLC. 58 ment 6b was coupled with acid chloride 755 with use of As an extension of this methodology, we were intertriethylamine and DMAP to afford the diester 16 in 92% ested in the synthesis of the macrolide core of cryptoyield (Scheme 2). The TBS and tert-butyl ester groups in phycin-52, the C6 gem-dimethyl-substituted derivative, compound 16 were deprotected simultaneously with which is under clinical development. Cryptophycin-52 excess TFA to provide hydroxy acid 17 in 90% yield. was first prepared by Barrow et al. utilizing an asymThe key N-acylazetidinone 8b was prepared as shown metric Sharpless epoxidation as a key step. 3 6 Later, the in Scheme 3. fl-Lactam 19, prepared from ethyl cyanoacsynthesis was modified by the group at Eli Lilly to etate in three steps in 42% overall yield, 60 -61 was coupled produce a synthesis that involved more than 30 discrete with tyrosine derivative 1836 with use of HBTU and DIEA synthetic operations. 59 Herein we describe a concise to furnish 20 in 91% yield. The Boc group of amine 20 total synthesis of dechlorocryptophycin-52 (4) using dimwas cleaved in quantitative yield with 4 M HC1 in 1,4-ethyl-2-azetidinone as a building block. dioxane to afford 8b. Coupling of hydroxy compound 17 and fl-lactam 8b family of antitumor macrolides. with HBTU and DIEA furnished the macrolide precursor 5b, which possessed all of the elements necessary for the Experimental Section formation of the macrocycle (Scheme 4). Initially, the (IS,2R)-l-{2-[(4-Methoxyphenyl)methoxylethyl}-2-mesimultaneous ring opening of the acyl-fl-lactam followed thylbut-3-enyl-(25)-4-methyl-Z-(1,1,2,2-tetramethyl-l-siby cyclization was tried with excess tetrabutylammonium lapropoxy)pentanoate (10). To bis-TBS protected L-leucic cyanide as reported earlier.
42 , 52 , 6 3 ,64 Interestingly, we later acid (6.5 g, 18 mmol) in CH 2 Cl 2 (30 mL) was added 15 drops found that the key macrolactonization can be achieved of DMF. 55 The solution was cooled to 0 *C and oxalyl chloride (3.2 mL, 36 mmol) was added dropwise with an addition using a "catalytic" amount of tetrabutylammonium cyafunnel. Vigorous bubbling was observed, which gradually nide or potassium cyanide to produce the 16-membered subsided. After addition was complete, the mixture was macrolide 21 in 65% yield. The final epoxidation of 21 warmed to room temperature and stirred at room temperature utilizing dimethyldioxirane (DMD) 57 provided a diasterfor 4.5 h. The mixture was concentrated in vacuo and used in eomeric mixture of dechlorocryptophycin-52 (4) in a 2:1 the next step. The crude acid chloride 7 was added dropwise (f8:a) ratio and in 75% yield. 40 ,4 8 The mixture was sepato a solution of alcohol 941 (1.5 g, 6 mmol), DMAP (2.2 g, 18 rated by reverse-phase HPLC. The preliminary biological mmol), and TEA (1.7 mL, 12 mmol) in CH 2 Cl 2 (15 mL) at 0°C . The reaction was stirred at 0 °C for 45 min at which time testing of the dechlorocryptophycin-52 analogue showed TLC indicated the disappearance of alcohol 9. The reaction good activity in both the tubulin assembly assay [IC 50 = was quenched with saturated aqueous NaHCO 3 and Et 2 O. The 3/pM; for Cr-i, IC 5 0 = 2.5/uM] and the cytotoxicity assay aqueous layer was extracted with Et 2 0. The combined organic [MCF-7 cell line, ICso = 0.3 nM; for Cr-1, IC 50 = 0.007 layers were dried (MgSO 4 ) and concentrated. Flash chromanM]. 65 . 66 The (x-isomer was found to be less active in both tography (hexanes to 95:5 hexanes:EtOAc) provided ester 10 as an oil (2.22 g, 78%). NMR 6 173.8, 165.3, 142.3, 138.6, 125.9, 116.3, 80 NMR 6 173.8, 159.1, 139.0, 130.4, 201 (100) , 189 (100); HRMS (FAB, mn/z) calcd for C25H4705Si 129.2 (2C), 115.8, 113.7 (2C), 74.3, 72.7, 70.7, 66.5, 55.2, 44.3, (M+ + H) 455.3193, found 455.3171. 41.6, 31.6, 25.7 (3C), 24.1, 23.4, 21.7, 18.2, 15.7, -4.6, -5 (25)-4-methylmg, 0.088 mrtol) was dissolved in CH 2 C1 2 (0.1 mL) and cooled 2-(1,1,2,2-tetramethyl-l-silapropoxy)pentanoate. Ester 10 to 0 0C. A TFA solution (1 M in CH 2 C1 2 , 1.1 mL) was added (276 mg, 0.577 mmol) was dissolved in CH2012 (2 mL) and H20 via syringe. The ice bath was removed after 2 h and the (0.1 mL). The mixture was cooled to 0 0C and DDQ (144 mg, reaction was continued with vigorous stirring. After 6 h, the 0.635 mmol) was added. After 30 min at 0 0C, the bath was reaction was found to be complete by TLC. Toluene (0.10 mL) removed and the mixture was stirred an additional 90 min at was added and the reaction was concentrated under vacuum room temperature. Additional CH2012 was added and the to provide the acid as a colorless oil (29 mg, 83% C NMR 6 173.8, 146.7, 138.5, 123.3, 116.5, 75.0, IH), 111, J= 4, 10, 11 Hz, 1H), 70.7, 44.4, 41.3, 34.5, 25.7 (3C), 24.1, 23.4, 21.7, 18.2, 16.1, (4-116.1, 74.5, 70.7, 58.5, 44.4, 41.9, 34.7, 25.7 (3C), 24.2, 23.4, methoxyphenyl) methyll-2-oxoethyl}carbamoyl)-1-((lR)-21. 7, 18.2, 16.2,-4.7, -5.3 .
1-methylprop-2-enyl)- (15) (262 mg, 0.69 mmol) were added consecutively. After 20 min, 0.397 mmol) was added. After 2 h, a 1:1 mixture of saturated the ice bath was removed and the mixture was stirred for 1 h. aqueous Na 2 S 2 0 3 and NH 4 Cl solutions was added. After 10
The reaction was quenched with saturated aqueous NH4C1 min of vigorous stirring, the mixture was diluted with CH2-solution and extracted with EtOAc. The combined organic C12 and H20. The aqueous phase was extracted with CH0C12.
layers were dried (MgSO4), filtered, and concentrated. Flash
The combined extracts were washed with saturated aqueous chromatography (80:20 to 50:50 hexanes:EtOAc) provided (2li-NaHCO 3 solution, dried (MgSO 4 ), filtered, and concentrated.
(tert-butoxy)-N((4-methoxyphenyl)methyl)-2-oxo-2-((2-oxoazeThe product was a colorless oil (76 mg, 81% NMR 6 199.2, 173.7, 138.2, 116.9, 71.7, 70.7, 349.1782. 45.5, 44.2, 41.3, 25.7 (3C), 24.1, 23.4, 21.7, 18.2. 15.5, -4.7, This compound (150 mg, 0.431 mmol) was dissolved in 4 N -5.4; MS (EI) m/z357 (M+ + H), 316; HRMS (FAB, m1z) calcd HCI in dioxane (4 mL) and stirred for 1.5 h. A precipitate for C1 9 H 3 7 0 4 Si (M+ + K) 357.2461, found 357.2463. formed and the reaction was concentrated to provide a light 3. Wittig Reaction of Intermediate Aldehyde To Form tan salt 8a. The acid (40 mg, 0.10 mmol) and salt 8a (40 mg, 12. tert-Butyl-(2E)-5-[(2S)-4-methyl-2-(1,1,2,2-tetramethyl-0.140 mmol) were placed in a flask and CH 3 CN (1 mL) was I-silapropoxy)pentanoyloxy]-(5S,6/•-6-methylocta-2,7-added. The solution was cooled to 0 0C and DIEA (52 ,L, 0.30 dienoate (12) . The aldehyde (80 mng, 0.22 mmol) was dissolved mmol) was added. When the solution was clear, HBTU (57 in CH2C12 (2.2 mL) and cooled to 0 *C. (tert-Butoxycarbonyling, 0.15 nmtol) was added and the reaction stirred for 30 min methylene)triphenylphosphorane 11 (101 mg, 0.27 minol) was at 0 0C and room temperature for 90 min. Saturated NaHCO 3 added. After 30 min at 0 0C and 90 min at room temperature, solution and CH2012 were added. The aqueous layer was the reaction was concentrated and purified by flash chromafurther extracted with CH2C12. The combined organic layers tography (95:5 hexane:EtOAc) to provide 12 as a colorless oil were dried (MgS0 4 ), filtered, and concentrated. Flash chro-(96 mg, 94% 15 Hz, 11), 5.75-5.66 2920 15 Hz, 11), 5.75-5.66 , 2900 15 Hz, 11), 5.75-5.66 , 2825 15 Hz, 11), 5.75-5.66 , 1770 15 Hz, 11), 5.75-5.66 , 1730 15 Hz, 11), 5.75-5.66 , 1690 15 Hz, 11), 5.75-5.66 , 1660 , 1620 cm-'; IH NMR (in, I1), 5.08 (br s, I), 5.07-5.03 (in, 11-), 4.99-4.95 (app q, 6 7.10-7 .07 (d, J= 9 Hz, 2H), 6.82-6.80 (d, J= 9 Hz, 2H), J= 7, 15 Hz, liD, J= 7 Hz, 7.09 (d, J= 8.6 Hz, 2H), J= 5.5 Hz, liD, J= 15 Hz, 1H), 11), J= 8.6 Hz, 2HD, J= 4.7, 10, 15 Hz, 5.34 NMR 6 172.8, 170.9, 170.8, 138.6, 130.3 (20), 127.2, 125.6, 116.3, 114.0 (2Q), 75.4, 70.7, 165.6, 158.5, 141.7, 136.7, 131.8, 130.2 (2Q), 128.6 (2Q), 128.5, 55.2, 54.5, 44.3, 40.8, 36.7, 36.6, 36.0, 34.0, 25.7 (3C), 24.1, 127.5, 126.1 (20), 125.0, 114.1 (2C), 76.6, 71.5, 55.2, 54.3, 42.2, 23.4, 21.7, 18.2, 16.3, ; MS (EI) mnz629 (M+): HRMS 39. 7, 36.4, 35.2, 34.2, 32.4, 24.3, 22.6, 21 as previously reported 40 with dimethyldioxirane 57 to obtain a methylpentanoate (5a). The silyl ether 13 (6.0 mg, 9.5 umol) 2:1 mixture (de was determined by HPLC Phenomenex Hywas dissolved in CHC01 (1 mL, dried over activated 4 A persil 5,u, C18, 150 x 3.2 mm, 254 nm, 3:2 CH 3 CN:H 2 0, 0.5 molecular sieves). BF 3 'Et 2 O (10 pL, 76.3 umol) was added via mL/min, retention time fP = 7 .2 min, a = 7.9 min) of epoxide syringe. After 1 h, CHC13 (5 mL) and saturated aqueous diastereomers (3.9 mg, 76%). laiD +37 (c 0.10, CHCl3).40 NaHCO 3 (2 mL) were added. The organic layers were dried tert-Butyl (2E,7E)-5-[(2S)-4-Methyl-2-(1,1,2,2-tetrame-(MgSO 4 ), filtered, and concentrated to provide clean 5a as an thyl-l-silapropoxy)pentanoyloxy]-(5S,61)-6-methyl-8-pheoil (4.4 mg, 88%). 1H NMR 6 7.10-7.08 (d, J= 9 Hz, 211, . To alcohol 6b 4
